Abstract Breast cancer has become the most common malignant tumor in women, which seriously threatens women’s physical and mental health. Recently, more and more studies have confirmed that the indicators such as neutrophils, platelets, lymphocytes, and the combined indicators such as the ratio of neutrophils to lymphocytes, the ratio of platelets to lymphocytes, and the ratio of lymphocytes to monocytes in blood routine are related to the therapeutic effect and prognosis of breast cancer. Blood routine indicators have the advantages of simplicity, economy and non-invasive, but there are also deficiencies such as lack of unified standards, small sample size, and unclear mechanism. This article reviews the research progress of the value of blood routine in the evaluation of prognosis of breast cancer.
YANG Yu GUO Jiani HUANG Mingde. Research progress on the value of blood routine in the prognostic evaluation of breast cancer#br#[J]. 中国医药导报, 2022, 19(4): 45-48,56.
[1] Sung H，Ferlay J，Siegel R，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] Ding Y，Chen X，Zhang Q，et al. Historical trends in breast Cancer among women in China from age-period-cohort modeling of the 1990-2015 breast Cancer mortality data [J]. BMC Public Health，2020，20（1）：1280.
[3] Yoon C，Park S，Cha Y，et al. Associations between absolute neutrophil count and lymphocyte-predominant breast cancer [J]. Breast （Edinburgh，Scotland），2020，50：141-148.
[4] Amgad M，Stovgaard E，Balslev E，et al. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group [J]. NPJ Breast Cancer，2020，6：16.
[5] Mahiddine K，Blaisdell A，Ma S，et al. Relief of tumor hypoxia unleashes the tumoricidal potential of neutrophils [J]. J Clini Invest，2020，130（1）：389-403.
[6] Antonio N，B?覬nnelykke-Behrndtz M，Ward L，et al. The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer [J]. EMBO J，2015，34（17）：2219-2236.
[7] Vicente Conesa M，Garcia-Martinez E，Gonzalez Billalabeitia E，et al. Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy [J]. Breast （Edinburgh，Scotland），2012，21（4）：468-474.
[8] Cho O，Chun M，Kim S，et al. Lymphopenia as a Potential Predictor of Ipsilateral Breast Tumor Recurrence in Early Breast Cancer [J]. Anticancer Res，2019，39（8）：4467-4474.
[9] Che Y，Zhang Y，Wang D，et al. Baseline Lymphopenia：A Predictor of Poor Outcomes in HER2 positive Metastatic Breast Cancer Treated with Trastuzumab [J]. Drug Des Devel Ther，2019，13：3727-3734.
[10] Ko S，Lee J，Bae S，et al. Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients [J]. Br J Cancer，2021，125（1）：119-125.
[11] Araki K，Ito Y，Fukada I，et al. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel [J]. BMC Cancer，2018，18（1）：982.
[12] Afghahi A，Purington N，Han S，et al. Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer [J]. Clin Cancer Res，2018，24（12）：2851-2858.
[13] Liu S，Fang J，Jiao D，et al. Elevated Platelet Count Predicts Poor Prognosis in Breast Cancer Patients with Supraclavicular Lymph Node Metastasis [J]. Cancer Manag Res，2020，12：6069-6075.
[14] Harano K，Kogawa T，Wu J，et al. Thrombocytosis as a prognostic factor in inflammatory breast cancer [J]. Breast Cancer Res Treat，2017，166（3）：819-832.
[15] Wen J，Ye F，Huang X，et al. Prognostic Significance of Preoperative Circulating Monocyte Count in Patients With Breast Cancer：Based on a Large Cohort Study [J]. Medicine，2015，94（49）：e2266.
[16] Huang Y，Cui M，Huang Y，et al. Preoperative platelet distribution width predicts breast cancer survival [J]. Cancer biomarkers：section A of Disease markers，2018， 23（2）：205-211.
[17] Onesti C，Josse C，Boulet D，et al. Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse [J]. Oncoimmunology，2020，9（1）：1761176.
[18] Lafrenie R，Speigl L，Buckner C，et al. Frequency of Immune Cell Subtypes in Peripheral Blood Correlates with Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy [J]. Clin Breast Cancer，2019，19（6）：433-442.
[19] Song X，Wang Y，Zhang A，et al. Advances in research on the interaction between inflammation and cancer [J]. J Intern Med Res，2020，48（4）：300060519895347.
[20] Greten F，Grivennikov S. Inflammation and Cancer：Triggers，Mechanisms，and Consequences [J]. Immunity，2019， 51（1）：27-41.
[21] Peng Y，Chen R，Qu F，et al. Low pretreatment lymphocyte / monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients [J]. Cancer Biol Ther，2020，21（2）：189-196.
[22] Elyasinia F，Keramati M，Ahmadi F，et al. Neutrophil-Lymphocyte Ratio in Different Stages of Breast Cancer [J]. Acta Med Iran，2017，55（4）：228-232.
[23] Bae S，Cha Y，Yoon C，et al. Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy [J]. Sci Rep，2020，10（1）：13078.
[24] Ding N，Huang J，Li N，et al. Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy [J]. BMC Cancer，2020，20（1）：235.
[25] Moon G，Noh H，Cho I，et al. Prediction of late recurrence in patients with breast cancer：elevated neutrophil to lymphocyte ratio （NLR） at 5 years after diagnosis and late recurrence [J]. Breast Cancer （Tokyo，Japan），2020， 27（1）：54-61.
[26] Koh C，Bhoo-Pathy N，Ng K，et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer [J]. Br J Cancer，2015，113（1）：150-158.
[27] Takada K，Kashiwagi S，Asano Y，et al. Prediction of Sentinel Lymph Node Metastasis Using the Platelet-to-lymphocyte Ratio in T1 Breast Cancer [J]. Anticancer Res，2020，40（4）：2343-2349.
[28] Cuello-López J，Fidalgo-Zapata A，López-Agudelo L，et al. Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer [J]. PLoS One，2018，13（11）：e0207224.
[29] Guo W，Lu X，Liu Q，et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients：An updated meta-analysis of 17079 individuals [J]. Cancer Medicine，2019，8（9）：4135-4148.
[30] Eren T，Karacin C，Ucar G，et al. Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients [J]. Medicine，2020， 99（22）：e20346.
[31] Azab B，Shah N，Radbel J，et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients [J]. Medical oncology （Northwood，London，England），2013，30（1）：432.
[32] Ugel S，Canè S，De Sanctis F，et al. Monocytes in the Tumor Microenvironment [J]. Annu Rev Pathol，2021， 16：93-122.
[33] Goto W，Kashiwagi S，Asano Y，et al. Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer [J]. BMC Cancer，2018，18（1）：1137.
[34] Ma Y，Zhang J，Chen X. Lymphocyte-to-Monocyte Ratio is Associated with the Poor Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy [J]. Cancer Manag Res，2021，13：1571-1580.
[35] Ligorio F，Fucà G，Zattarin E，et al. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 （HER2）-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab [J]. Cancers （Basel），2021，13（8）：1964.
[36] Deng Y，Li W，Liu X，et al. The combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients with resected breast cancer [J]. Medicine，2020，99（18）：e18755.
[37] Wang L，Zhou Y，Xia S，et al. Prognostic value of the systemic inflammation response index （SIRI） before and after surgery in operable breast cancer patients [J]. Cancer Biomarkers，2020，28（4）：537-547.
